Vertex Pharmaceuticals (VRTX)
440.12
+0.75 (0.17%)
NASDAQ · Last Trade: May 13th, 2:31 PM EDT
Detailed Quote
Previous Close | 439.37 |
---|---|
Open | 437.53 |
Bid | 439.81 |
Ask | 440.12 |
Day's Range | 429.54 - 442.12 |
52 Week Range | 377.85 - 519.88 |
Volume | 1,700,065 |
Market Cap | 114.18B |
PE Ratio (TTM) | -113.14 |
EPS (TTM) | -3.9 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 1,956,575 |
Chart
About Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals is a biotechnology company that focuses on discovering, developing, and commercializing innovative therapies to treat serious diseases. With an emphasis on cystic fibrosis, Vertex has pioneered groundbreaking treatments that significantly improve the lives of patients with this genetic disorder. In addition to its work in cystic fibrosis, the company is exploring potential therapies for other rare diseases, including pain management and beta-thalassemia. Vertex is dedicated to advancing scientific research and collaborating with the global medical community to bring new solutions to unmet medical needs. Read More
News & Press Releases
Via Benzinga · May 13, 2025
Via The Motley Fool · May 13, 2025
It's still unclear how President Donald Trump plans to tie drug prices in the U.S. to international prices.
Via Investor's Business Daily · May 12, 2025
Via Benzinga · May 12, 2025
Via The Motley Fool · May 12, 2025
The worst performing large-cap stocks last week: ARGENX, VRTX, SMMT, MMYT, REGN, RKT, BNTX, AFRM, FNF, LLY, AUR, DASH. Any in your portfolio?
Via Benzinga · May 11, 2025
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Vertex Pharmaceuticals (NASDAQ:VRTX).
Via StockStory · May 8, 2025
Curious about the top performers within the S&P500 index one hour before the close of the markets on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Via Chartmill · May 7, 2025
Stay informed about the performance of the S&P500 index in the middle of the day on Wednesday. Uncover the top gainers and losers in today's session for valuable insights.
Via Chartmill · May 7, 2025
Via The Motley Fool · May 7, 2025
Markets slide on vaccine regulation fears, trade uncertainty, and cautious earnings despite strong tech and consumer stock moves.
Via Chartmill · May 7, 2025
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Via StockStory · May 7, 2025
Vertex posted Q1 EPS and sales below estimates but raised its 2025 revenue outlook, driven by CF drug demand and new product launches in the U.S.
Via Benzinga · May 6, 2025
Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session.
Via Chartmill · May 6, 2025
Wall Street edged lower by midday Tuesday as uncertainty surrounding trade policies lingered, with investors adopting a cautious approach ahead of Wednesday’s Federal Reserve meeting.
Via Benzinga · May 6, 2025
Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session.
Via Chartmill · May 6, 2025
Wondering which stocks are making significant price gaps? Explore the S&P500 index on Tuesday to find the gap up and gap down stocks in today's session.
Via Chartmill · May 6, 2025
The company paused a study of a cystic fibrosis treatment, right on the heels of a scrapped type 1 diabetes program.
Via Investor's Business Daily · May 6, 2025